Added to YB: 2026-07-02
Pitch date: 2026-06-30
MDP.TO [neutral]
Medexus Pharmaceuticals Inc.
Author Info
No bio for this author
Company Info
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases.
Market Cap
CAD 113.7M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
8.31
P/E
-48.48
EV/Sales
1.30
Sector
Pharmaceuticals
Category
growth
Weekly #11: Most Interesting D-Sheets from the Past Week - Medexus Pharmaceuticals Inc.
MDP.TO (update): North American rare-disease pharma pivoting to GRAFAPEX (allo-HSCT drug). FY26 rev -8.3% to $99.3M, adj EBITDA $16.5M, GAAP loss on Gleolan return/Rupall generics, but Q4 adj EBITDA +87%, GM 53.8%. GRAFAPEX guided ~2.7x to $30-32M FY27; 54/74 centers reordered. Net debt/EBITDA 0.95x, buying back stock. Risks: cash fell to $6.5M, rising R&D/SG&A, lumpy quarters. ~$94.6M cap.
Read full article (1 min)